BIOMAKERS Raises Additional $8 Million to Scale Global Precision Oncology Intelligence Platform

BIOMAKERS再获800万美元融资，用于扩展全球精准肿瘤学情报平台规模

SAN FRANCISCO, January 20, 2026-- BIOMAKERS, a precision medicine and oncology intelligence company headquartered in San Francisco, today announced the closing of an additional $8 million. The financing marks a key inflection point as the company transitions from building a differentiated global diagnostics and data infrastructure to scaling an AI-native platform – while continuing to expand its comprehensive molecular testing reach across Latin America – designed to accelerate drug and diagnostic development, improve clinical trial execution, and enable precision oncology at global scale..

旧金山，2026年1月20日——总部位于旧金山的精准医疗和肿瘤学智能公司BIOMAKERS今日宣布完成了额外800万美元的融资。此次融资标志着公司发展的一个关键转折点，因为它从构建差异化的全球诊断和数据基础设施，过渡到扩展一个以人工智能为核心的平台——同时继续扩大其在拉丁美洲的全面分子检测覆盖范围——旨在加速药物和诊断工具的开发、改善临床试验执行，并在全球范围内实现精准肿瘤学。

BIOMAKERS has built an integrated oncology ecosystem combining large-scale molecular diagnostics, longitudinal real-world clinical data, and a diverse, deeply annotated tumor biobank. Operating across more than 20 countries, the company links genomic data directly to biospecimens and clinical outcomes, creating an intelligence layer that life sciences companies can use to de-risk R&D, expand trial access, and improve decision-making across the drug development lifecycle..

BIOMAKERS构建了一个集成的肿瘤学生态系统，结合了大规模分子诊断、纵向真实世界临床数据以及多样化且深度注释的肿瘤生物样本库。公司业务遍及20多个国家，将基因组数据直接与生物样本和临床结果相连接，创建了一个智能层，生命科学公司可以利用这一智能层来降低研发风险、扩大试验获取渠道，并改善药物开发生命周期中的决策过程。

With its core infrastructure now in place, BIOMAKERS is entering a new phase focused on platform scalability and monetization. The company is deploying proprietary AI technologies to structure and harmonize real-world clinical data directly from hospital electronic medical records, unlocking previously inaccessible biological and clinical signals at scale, positioning BIOMAKERS as critical infrastructure for global precision oncology research and development..

随着其核心基础设施现已到位，BIOMAKERS正进入一个专注于平台可扩展性和货币化的新阶段。该公司正在部署专有的人工智能技术，直接从医院电子病历中提取、构建和整合真实世界的临床数据，大规模解锁以往无法获取的生物学和临床信号，使BIOMAKERS成为全球精准肿瘤学研发的关键基础设施。

To support this next phase, BIOMAKERS appointed Ezequiel Renzulli as Chief Operating Officer. Ezequiel previously held senior leadership roles at BillionToOne and Tempus, where he helped scale AI-driven diagnostics and data platforms for life science partners.

为了支持这一下一阶段，BIOMAKERS 任命了埃泽基尔·伦祖利 (Ezequiel Renzulli) 为首席运营官。埃泽基尔此前在 BillionToOne 和 Tempus 担任过高级领导职务，曾帮助生命科学合作伙伴扩展了基于人工智能的诊断和数据平台。

Consuelo Valverde, Founder and Managing Partner of Endurance28, said, “We believed in BIOMAKERS early because the team showed a rare combination of long-term vision and execution in a highly complex market. They’ve demonstrated exceptional discipline in combining science, data, and operations into a scalable platform while remaining focused on long-term value creation.”.

Endurance28 的创始人兼管理合伙人孔苏埃洛·瓦尔韦德 (Consuelo Valverde) 表示：“我们很早就相信了 BIOMAKERS，因为该团队在高度复杂的市场中展现了罕见的长期愿景与执行力。他们展示了卓越的纪律性，将科学、数据和运营结合到一个可扩展的平台中，同时始终专注于长期价值创造。”

BIOMAKERS’ platform includes a tumor biobank of more than 100,000 cases and growing, high-throughput genomic testing and molecular profiling capabilities, and a continuously growing clinical-genomic dataset representing under-sampled patient populations essential for regulatory relevance and therapeutic development.

BIOMAKERS的平台包括一个超过10万例且不断增长的肿瘤生物样本库、高通量基因组检测和分子分析能力，以及一个持续增长的临床基因组数据集，这些数据代表了对监管相关性和治疗开发至关重要的采样不足的患者群体。

By maintaining direct, longitudinal connections to patients, physicians, and healthcare institutions, the company enables partners to move seamlessly from data generation to biological insight and clinical execution..

通过与患者、医生和医疗机构保持直接的纵向联系，该公司使合作伙伴能够无缝地从数据生成过渡到生物学洞察和临床执行。

“Many companies provide data, but few can link genomic insights directly back to real patient samples at scale,” said Ben Freeberg, General Partner at Oncology Ventures. “BIOMAKERS has built an end-to-end system that creates durable value for pharma partners while enabling faster, more effective research and development.”.

“许多公司提供数据，但很少有公司能够大规模地将基因组学洞察直接链接到真实的患者样本，”肿瘤学风险投资公司的普通合伙人本·弗里伯格表示。“BIOMAKERS构建了一个端到端的系统，为制药合作伙伴创造了持久的价值，同时使研究和开发更快速、更有效。”

“This financing marks a transition from building infrastructure to scaling a global platform,” said Nicolás Kirchuk, Co-Founder and Chief Executive Officer of BIOMAKERS. “We’ve spent years assembling the data, an integrated diagnostic network, and clinical connectivity required to power precision oncology.

“这笔融资标志着从建设基础设施到扩展全球平台的转变，”BIOMAKERS联合创始人兼首席执行官尼古拉斯·基尔丘克表示。“我们花费了数年时间收集数据，构建了一个综合诊断网络和临床连接，为精准肿瘤学提供了支持。”

Now, with AI at the core of our platform, we’re positioned to make that intelligence broadly accessible, accelerating the development of next-generation therapies and emerging diagnostic tools worldwide.”.

现在，随着人工智能成为我们平台的核心，我们有能力广泛提供这种智能，加速全球下一代疗法和新兴诊断工具的开发。

This round includes participation from Labcorp Venture Fund, Oncology Ventures, Endurance28, Zentynel, Sonen Capital, Sky High Fund, and other strategic investors with deep expertise across life sciences, healthcare technology, and data-driven platforms.

本轮包括来自Labcorp风险基金、肿瘤学风险投资公司、Endurance28、Zentynel、Sonen Capital、Sky High Fund以及其他在生命科学、医疗技术和数据驱动平台方面具有深厚专业知识的战略投资者的参与。

About BIOMAKERS

关于BIOMAKERS

BIOMAKERS is a precision medicine and oncology intelligence company transforming clinical and genomic information into actionable insights for therapeutic and diagnostic development. Headquartered in San Francisco, with clinical laboratories in Mexico, Brazil, and Argentina, BIOMAKERS operates across Latin America and the United States, enabling global partners to access diverse, high-quality data and biospecimens at scale..

BIOMAKERS是一家精准医疗和肿瘤学情报公司，将临床和基因组信息转化为治疗和诊断开发的可行性见解。公司总部位于旧金山，在墨西哥、巴西和阿根廷设有临床实验室，业务覆盖拉丁美洲和美国，使全球合作伙伴能够大规模获取多样化、高质量的数据和生物样本。

Contact:

联系：

Media Contact

媒体联系人

info@biomakers.io

info@biomakers.io

www.biomakers.io

www.biomakers.io